Drug profile · INN
erlotinib
ERLOTINIB ARX
erlotinib (ERLOTINIB ARX) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EB02
Patents linked 0
Pipeline programs 15
News articles 0
Drug details — erlotinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 15
- Data quality
- 0.83
Quick answer
erlotinib (ERLOTINIB ARX) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN erlotinib
Brand ERLOTINIB ARX
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EB02
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is erlotinib?
erlotinib (ERLOTINIB ARX) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for erlotinib?
ERLOTINIB ARX is a marketed brand name for erlotinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.